Publication | Closed Access

Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages

Intracranial HemorrhagesThrombosisMedicineHematologyAndexanet AlfaHemostasisBrain InjuryNeurologyNeurovascular DiseaseBleeding DisorderCerebral Blood FlowCoagulopathyStrokeAnticoagulantAnesthesiologyHealth Sciences